Recursion Pharmaceuticals reports $30 million milestone payment and $785 million cash balance for Q3 2025
Reuters
Nov 05
<a href="https://laohu8.com/S/RXRX">Recursion</a> Pharmaceuticals reports $30 million milestone payment and $785 million cash balance for Q3 2025
Recursion Pharmaceuticals reported a net loss of $162.3 million for the third quarter of 2025, compared to a net loss of $95.8 million for the same period in 2024. Total revenue for the quarter was $5.2 million, down from $26.1 million in the third quarter of 2024, primarily due to milestone payment timing under collaboration agreements. Research and development expenses increased to $121.1 million from $74.6 million year-over-year, mainly due to the acquisition of rights to REC-102 and the business combination with Exscientia in November 2024. Net cash used in operating activities was $325.7 million for the first nine months of 2025, compared to $243.7 million for the same period in 2024. As of October 9, 2025, the company held approximately $785 million in cash and cash equivalents. Recursion achieved a $30 million milestone payment from Roche and Genentech for delivering a whole-genome map of microglial immune cells and has reached over $500 million in milestone and upfront payments across all partnerships and collaborations.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9569015-en) on November 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.